Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks.

Cancer Chemother Pharmacol

Department of Clinical Pharmacology and Therapeutics, Roswell Park Memorial Institute, New York State Department of Health, Buffalo 14263.

Published: May 1989

A phase I study was carried out on a new water-soluble nitrosourea, 6-deoxy-3,5 di-O-methyl 6-(3 methyl-3-nitrosoureido)-alpha-D-glucofuranoside (EDMN, CGP 6809), given every 2 weeks. A total of 18 patients received doses of 1, 2, 3, and 3.75 g/m2 as a 2- to 5-h infusion. Toxicity principally involved nausea and vomiting, hepatotoxicity, and abdominal pain. There was no evidence of cumulative toxicity. The dose of 3.75 g/m2 was not exceeded because in a previous phase I study, 4.5 g/m2 every 6 weeks was not tolerated; the recommended dose for phase II studies is 3.75 g/m2 every 2 weeks.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF00451655DOI Listing

Publication Analysis

Top Keywords

375 g/m2
12
cgp 6809
8
6809 weeks
8
phase study
8
g/m2 weeks
8
phase
4
phase trial
4
trial nitrosourea
4
nitrosourea cgp
4
weeks
4

Similar Publications

Importance: Assisted reproductive technology (ART) has been widely used for treatment of infertility and has brought millions of births worldwide. The health of offspring conceived by ART has been of much concern, and adverse cardiovascular health outcomes have been reported by previous studies.

Objective: To assess the cardiovascular health of children conceived by ART.

View Article and Find Full Text PDF

Aims: Native valve aortic stenosis is associated with adverse remodelling of the left ventricle and remodelling is stopped or even reversed with aortic valve replacement (AVR). However, the degeneration of bioprostheses and development of structural valve deterioration (SVD) may affect this.

Methods And Results: To assess the association with SVD, remodelling and outcome 451 patients from a single surgical centre who had undergone AVR with a Mitroflow pericardial bioprosthesis were studied.

View Article and Find Full Text PDF

Background: There is increasing evidence that MTX-based chemotherapy is superior to HD-MTX alone. Rituximab (RTX) is effective in a variety of B-cell lymphomas and may enter the brain. The purpose of this study is to evaluate the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).

View Article and Find Full Text PDF

Purpose: High-dose methotrexate based chemotherapy is the standard treatment for patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The role of rituximab is controversial because of its large size, which limits its penetration of the blood-brain barrier. In this study, we investigated the efficacy and tolerability of adding rituximab to methotrexate-cytarabine-dexamethasone combination therapy (RMAD regimen).

View Article and Find Full Text PDF

Background: Sudden cardiac death (SCD) is the leading cause of death in maintenance hemodialysis (HD) patients, but there is little information about underlying risk factors.

Objectives: Evaluate the association between clinical and echocardiographic variables with SCD on HD patients.

Methods: Retrospective nested case-control study on chronic HD patients who were prospectively followed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!